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The pathogenesis of human non-alcoholic fatty liver disease (NAFLD) remains unclear, 
in particular in the context of its relationship to insulin resistance and visceral obesity. 
Work on the carcinoembryonic antigen-related cell adhesion molecule 1 (CEACAM1) in 
mice has resolved some of the related questions. CEACAM1 promotes insulin clearance 
by enhancing the rate of uptake of the insulin-receptor complex. It also mediates a 
negative acute effect of insulin on fatty acid synthase activity. This positions CEACAM1 
to coordinate the regulation of insulin and lipid metabolism. Fed a regular chow diet, 
global null mutation of Ceacam1 manifest hyperinsulinemia, insulin resistance, obesity, 
and steatohepatitis. They also develop spontaneous chicken-wire fibrosis, characteristic 
of non-alcoholic steatohepatitis. Reduction of hepatic CEACAM1 expression plays a 
significant role in the pathogenesis of diet-induced metabolic abnormalities, as bolstered 
by the protective effect of hepatic CEACAM1 gain-of-function against the metabolic 
response to dietary fat. Together, this emphasizes that loss of hepatic CEACAM1 links 
NAFLD to insulin resistance and obesity.
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PHYSiOLOGiC ReGULATiON OF CARCiNOeMBRYONiC 
ANTiGeN-ReLATeD CeLL ADHeSiON MOLeCULe 1 (CeACAM1)
The CEACAM1 is a transmembrane glycoprotein that undergoes phosphorylation by the insulin 
receptor tyrosine kinase (1). Among insulin target tissues, CEACAM1 is predominantly expressed 
in the liver (2). This is consistent with its role in promoting insulin clearance, which occurs mostly 
in liver and to a lower extent in kidney. Consistent with the important role of the liver in regulating 
insulin and lipid metabolism, Ceacam1 transcription is coordinately regulated by insulin and fatty 
acids during fasting–refeeding conditions, with fatty acids at fasting repressing it via a mechanism 
depending on the peroxisome proliferator-activated receptor alpha (PPARα) (3, 4) and insulin 
inducing it in the first few hours of refeeding (3, 5).
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CeACAM1 PROMOTeS iNSULiN 
CLeARANCe AND MeDiATeS AN ACUTe 
NeGATive eFFeCT OF iNSULiN ON 
HePATiC DE NOVO LiPOGeNeSiS
Insulin is released from pancreatic β-cells in a pulsatile manner 
(6). The acute rise of insulin in the portal vein causes phospho-
rylation and activation of the insulin receptor tyrosine kinase in 
the hepatocyte (7, 8). This, in turn, leads to phosphorylation of 
substrates, including CEACAM1 (1). Upon its phosphorylation, 
CEACAM1 promotes receptor-mediated insulin uptake into 
clathrin-coated pits/vesicles of the hepatocyte to be eventually 
degraded and cleared from the blood (9, 10). This process medi-
ates the rapid extraction of ~50% of secreted insulin through its 
first pass into the liver.
Internalization of phosphorylated CEACAM1 as part of the 
insulin-receptor complex leads to its binding to fatty acid syn-
thase (FASN) (11), a key enzyme that catalyzes the conversion 
of malonyl-CoA to palmitic acid during de novo lipogenesis. 
CEACAM1 association downregulates FASN enzymatic activity 
and restricts hepatic de novo lipogenesis, likely to protect the liver 
against the potential lipogenic effect of approximately twofold to 
threefold higher level of insulin in the portal than the systemic 
circulation (12). Thus, CEACAM1 phosphorylation by the insu-
lin receptor in response to acute rise of insulin constitutes a key 
mechanism that underlies the maintenance of physiologic insulin 
levels, at the same time as mediating a suppressive acute effect of 
insulin on lipogenesis in liver. Combined, this restricts hepatic 
lipid production under normal physiologic conditions; assign-
ing a major role for CEACAM1 in integrating the regulation of 
insulin and lipid metabolism in the hepatocyte. Under condi-
tions of hyperinsulinemia, the pulsatility of insulin secretion is 
compromised (6), limiting insulin signaling in the hepatocyte, 
including CEACAM1 phosphorylation, and subsequently, the 
acute negative effect of insulin on FASN activity is removed to 
contribute to hyperinsulinemia-driven lipogenesis (11). This 
paradigm emphasizes the contrast between the previously unap-
preciated suppressive effect of acute insulin pulses on fatty acid 
synthesis and the well-recognized positive effect of chronically 
elevated levels of insulin on lipogenic genes’ expression by the 
coordinated action of sterol regulatory element-binding protein 
(SREBP1c) (13) and the upstream stimulatory factor 1 (14). 
Suppression of hepatic FASN activity by pulsatile insulin release 
proposes to include elevation in de novo lipogenesis as a manifest 
of hepatic insulin resistance in addition to increased hepatic glu-
cose production (via glycogenolysis and gluconeogenesis) (8, 15).
MUTATiNG CeACAM1 iN LiveR  
CAUSeS iNSULiN ReSiSTANCe AND 
NON-ALCOHOLiC STeATOHePATiTiS 
(NASH)
Mice with liver-specific inactivation (L-SACC1) or with global 
null mutation of Ceacam1 (Cc1−/−) exhibit impairment in insulin 
clearance leading to chronic hyperinsulinemia and systemic 
insulin resistance (owing to downregulation of insulin receptor 
expression) (16–18). They also exhibit elevated lipid production 
in liver and redistribution to the white adipose tissue to be stored; 
thus, contributing to visceral obesity and increased release of free 
fatty acid (FFA) and adipokines (19).
Mutant Ceacam1 mice also develop inflammation in 
liver, in part due to the loss of the anti-inflammatory effect of 
CEACAM1 (20), apoptosis, and oxidative stress. Additionally, 
they manifest chicken-wire bridging fibrosis, a characteristic 
feature of NASH, even when fed a standard chow diet, making 
them rare mouse models of spontaneous fibrosis on the C57BL/6J 
genetic background. The underlying mechanisms of fibrosis in 
Ceacam1 mutants are the subject of intense investigations in our 
laboratories.
DieTARY FAT ReDUCeS HePATiC 
CeACAM1 eXPReSSiON iN C57BL/6J 
MiCe
In uncomplicated obesity with low-grade insulin resistance, FFA 
are mobilized from white adipose tissue mainly to the liver to be 
removed by β-oxidation (21). This is supported by experimental 
evidence in rodents showing occurrence within few days of the 
initiation of high-fat intake as a result of dysregulated hypotha-
lamic control in the adipose tissue (22). While this early lipolysis 
occurs in the absence of insulin resistance in the adipose tissue, 
the released FFA can rapidly initiate hepatic insulin resistance 
(23), in part by activating PKCδ-mediated pathways (24). 
As the nutritional burden persists, hepatic lipotoxicity develops 
in response to progressively compromised β-oxidation relative 
to re-esterification. Concomitantly, hepatic insulin resistance 
progresses into systemic insulin resistance to be manifested in 
peripheral tissues, including the white adipose tissue with ensu-
ing advancement of a pro-inflammatory state (25).
Recent reports from our laboratories show that high-fat diet 
progressively reduces hepatic CEACAM1 level in C57BL/6J mice 
until it reaches >50% after 3 weeks, at which point, insulin clear-
ance is impaired and hyperinsulinemia develops with attendant 
hepatic insulin resistance and steatohepatitis (26). Consistent 
with the key role for CEACAM1 in diet-induced insulin resist-
ance and hepatosteatosis, adenoviral-mediated redelivery of 
wild-type, but not phosphorylation-defective CEACAM1 to the 
liver, completely reverses these metabolic abnormalities even 
while maintaining mice on a high-fat diet (27), demonstrating 
a causative role for the decrease in hepatic CEACAM1 level in 
sustaining diet-induced systemic insulin resistance and hepatic 
steatosis. That impairment of insulin clearance plays a significant 
role in hepatic insulin resistance in response to high-fat diet has 
recently been demonstrated in Asian men (28). Using a two-step 
hyperinsulinemic-euglycemic clamp, Bakker et  al. (28) showed 
that in contrast to age- and sex-matched Caucasians, young and 
healthy South Asian men develop impairment of insulin clear-
ance as well as hepatic insulin resistance in the absence of other 
metabolic alterations in skeletal muscle and white adipose tissue 
following 5 days of a high-fat Western diet intake. Several other 
studies in humans (28) as well as dogs (29) have supported the 
FiGURe 1 | A pivotal role for carcinoembryonic antigen-related cell 
adhesion molecule 1 (CeACAM1) reduction in the pathogenesis of 
fatty liver disease and obesity. Reduction or mutation of Ceacam1 in the 
liver results in decreased insulin clearance from the portal circulation. 
Reduced clearance leads to hyperinsulinemia followed by insulin resistance 
(owing to downregulation of the insulin receptor) and increased hepatic 
lipogenesis. Elevation in hepatic lipogenesis leads to lipid redistribution to the 
while adipose depot to increase visceral adiposity. This leads to 
hyperleptinemia, which along with hyperinsulinemia, increases food intake 
and energy imbalance, further exacerbating obesity. Hyperinsulinemia drives 
hepatic lipogenesis and fat accumulation in liver.
3
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findings that defective hepatic insulin clearance is implicated in 
diet-induced insulin resistance.
The decrease in hepatic CEACAM1 by high-fat diet is attrib-
uted to lipolysis-derived FFA, in agreement with reducing hepatic 
CEACAM1 levels by intralipid–heparin infusion (24) and the 
negative effect of FFA on insulin clearance (30, 31). The underly-
ing mechanism of CEACAM1 repression by FFA is via PPARα 
activation (4). In the presence of normoinsulinemia, this provides 
a positive feedback mechanism on fatty acid β-oxidation as it 
limits the negative effect of CEACAM1 on FASN activity (11) and 
subsequently, reduces malonyl-CoA-mediated inhibition of fatty 
acids translocation to the mitochondria (3). When CEACAM1 
level is reduced by >50%, hepatic insulin clearance fails and 
chronic hyperinsulinemia develops, causing hepatic insulin 
resistance, at least in part by downregulating insulin receptors in 
the hepatocyte (32, 33) and triggering de novo lipogenesis by acti-
vating SREBP1c-mediated transcription of lipogenic genes (13), 
including acetyl-CoA carboxylase (ACC), a limiting enzyme in 
lipid biosynthesis. Elevation in ACC level (and activity) induces 
malonyl-CoA level, which in turn, inhibits fatty acid transport 
to the mitochondria and β-oxidation. Potentially contributing 
to the downregulation of β-oxidation under hyperinsulinemic 
conditions is the maintenance of insulin-stimulated phospho-
rylation and inactivation of Foxa2-mediated suppression of the 
transcription of genes involved in fatty acid β-oxidation (34, 35). 
Collectively, this limits fatty acid β-oxidation while promoting 
de novo lipogenesis, leading to hepatosteatosis. With the loss of 
the potential counter-regulatory anti-inflammatory function of 
CEACAM1, this causes a more robust change in the inflammatory 
milieu of the liver and steatohepatitis develops. Together, the data 
identify reduction in CEACAM1 expression as a novel molecular 
underpinning of the integrated regulation of lipid oxidation and 
hepatic insulin resistance (gluconeogenesis) by FFA mobilization 
from white adipose tissue (36–38).
ReDUCeD HePATiC CeACAM1 LeveLS 
CAUSeS OBeSiTY BY CONTRiBUTiNG  
TO eNeRGY iMBALANCe
High-fat diet represses hepatic CEACAM1 levels to impair 
insulin clearance and cause hyperinsulinemia that in turn, drives 
increased hepatic lipid production and output to the white adipose 
depot for storage (39). This is consistent with the well-accepted 
association of hyperinsulinemia and liver steatosis with high 
plasma Apolipoprotein B levels and visceral obesity in humans 
and rodents (40–45). Together with visceral obesity, sustained 
hyperinsulinemia reduces glucose transporter 4-mediated glu-
cose transport to cause insulin resistance in adipose tissue (46), 
as supported by hyperinsulinemic-euglycemic clamp analysis in 
Ceacam1 mutants (16–18, 47) and in the diet-induced model (26).
Consistent with the finding that reduction of hepatic 
CEACAM1 plays a critical role in diet-induced altered meta-
bolic response, transgenic protection of hepatic CEACAM1 in 
L-CC1 mice prevents hyperinsulinemia, insulin resistance, and 
hepatosteatosis in response to high-fat diet (26). It also limits the 
size of adipocytes and total fat mass by countering the negative 
effect of high-fat diet on energy expenditure and spontaneous 
physical activity (26). Similarly, adenoviral-redelivery of wild-
type CEACAM1 in the liver protects energy balance against 
high-fat intake, thereby reversing the gain in body weight and 
visceral adiposity (27). Given that CEACAM1 is not detected in 
the adipocyte at the protein level (2), it is likely that the gain-
of-function of hepatic CEACAM1 drives this positive effect on 
energy expenditure and adipose tissue biology (limited adipocyte 
size, fibrosis, and inflammation) (27, 39). The beneficial effect of 
hepatic CEACAM1 gain-of-function on insulin response in white 
adipose tissue could be mediated, at least in part, by the rise in 
plasma FGF21 (48, 49) that induces the locomotor activity (50) 
and energy expenditure (51, 52).
Both L-SACC1 and Cc1−/− mutant mice display visceral obesity 
and a higher body mass than their wild-type counterparts (16–18). 
Visceral obesity, which is partly caused by elevated hepatic lipid 
production and redistribution to white adipose tissue (19), leads 
to hyperleptinemia, which could in turn, alter response to leptin 
and cause energy imbalance. Consistently, global Cc1−/− null mice 
develop elevated production and secretion of leptin from their 
expanded while adipose depot in addition to increased total fat 
mass and obesity resulting from hyperphagia and reduced spon-
taneous physical activity (53). In addition to leptin resistance, 
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hyperinsulinemia also contributes to the obesity phenotype in 
these mice, at least in part, by inducing hypothalamic FASN level 
and activity (53), which in turn, causes hyperphagia (54) and 
lower physical activity (55, 56). Together, this demonstrates that 
altered CEACAM1-dependent insulin clearance pathways drive 
hyperinsulinemia-mediated link of hepatic steatosis to visceral 
obesity and increased total fat mass.
CONCLUDiNG ReMARKS
The mechanisms underlying the pathogenesis of non-alcoholic 
fatty liver disease (NAFLD) in humans remain unclear (57) 
and whether insulin resistance plays a role in NAFLD has been 
debated, owing to the lack of appropriate animal models that 
replicate all features of the human disease and its progression to 
NASH (58, 59). As summarized in this review, our laboratory has 
demonstrated in the last couple of decades that loss in hepatic 
CEACAM1 expression and its defective phosphorylation impair 
insulin clearance and subsequently, play a pivotal role in insulin 
resistance, fatty liver disease, and obesity (Figure 1) (9, 10, 16–19, 
25, 27, 39, 53, 60, 61). Demonstration of a role for impaired insu-
lin clearance in insulin resistance in human disease is emerging 
(62–65). In this regard, compromised hepatic insulin extraction 
has been shown to constitute a risk factor for obesity (66, 67), 
type 2 diabetes (68), metabolic syndrome (65, 69), and fatty liver 
disease (70). The study by Lee (71) showing a marked decline in 
hepatic CEACAM1 levels in patients with high-grade fatty liver 
and obesity coupled with our mechanistic studies demonstrating 
that redelivering CEACAM1 to the liver reverses diet-induced 
insulin resistance, fatty liver, and visceral obesity (27) emphasizes 
a critical role for CEACAM1 in metabolic control. Of note, while 
our studies show that reduction of hepatic CEACAM1 causes 
insulin resistance, hepatosteatosis, and visceral obesity, they 
also show that diet-induced visceral obesity represses hepatic 
CEACAM1 to cause fat accumulation in liver and insulin 
resistance (3, 26, 27). Further emphasizing the metabolic role of 
hepatic CEACAM1, liver-specific overexpression of CEACAM1 
curbs the metabolic abnormalities caused by high-fat diet and 
prevents insulin resistance and hepatosteatosis (26). Similarly, 
adenoviral-mediated redelivery of CEACAM1 to the liver reverses 
diet-induced metabolic derangement (27). Collectively, this posi-
tions the loss of hepatic CEACAM1 expression (and its resulting 
hyperinsulinemia and insulin resistance) on the crossroad of the 
pathogenesis of NAFLD and obesity.
AUTHOR CONTRiBUTiONS
GH wrote a first draft of the manuscript. HG, SG, HM, KR, QA-S, 
TB, DZ contributed to the writing. RG and LY reviewed the 
manuscript. SN was responsible for revising the manuscript. SN 
had full access to all the data of the study and takes responsibility 
for the integrity and accuracy of data analysis and the decision to 
submit and publish the manuscript.
FUNDiNG
This work was supported by grants from the NIH: R01 
DK054254, R01 DK083850, and R01 HL112248 (to SN) and K99/
R00-DK077449 and R01 DK099593 (to LY). It was also supported 
by a fund from the Heritage College of Osteopathic Medicine 
(to GH). The work was also supported by fellowships from the 
Middle-East Diabetes Research Center (to HG and SG).
ReFeReNCeS
1. Najjar SM, Philippe N, Suzuki Y, Ignacio GA, Formisano P, Accili D, et  al. 
Insulin-stimulated phosphorylation of recombinant pp120/HA4, an endog-
enous substrate of the insulin receptor tyrosine kinase. Biochemistry (1995) 
34:9341–9. doi:10.1021/bi00029a009 
2. Najjar SM. Regulation of insulin action by CEACAM1. Trends Endocrinol 
Metab (2002) 13:240–5. doi:10.1016/S1043-2760(02)00608-2 
3. Ramakrishnan SK, Khuder SS, Al-Share QY, Russo L, Abdallah SL, Patel 
PR, et  al. PPARalpha (peroxisome proliferator-activated receptor alpha) 
activation reduces hepatic CEACAM1 protein expression to regulate fatty acid 
oxidation during fasting-refeeding transition. J Biol Chem (2016) 291:8121–9. 
doi:10.1074/jbc.M116.714014 
4. Ramakrishnan SK, Russo L, Ghanem SS, Patel PR, Oyarce AM, Heinrich G, 
et al. Fenofibrate decreases insulin clearance and insulin secretion to maintain 
insulin sensitivity. J Biol Chem (2016) 291(46):23915–24. doi:10.1074/jbc.
M116.745778 
5. Najjar S, Boisclair Y, Nabih Z, Philippe N, Imai Y, Suzuki Y, et  al. Cloning 
and characterization of a functional promoter of the rat pp120 gene, encod-
ing a substrate of the insulin receptor tyrosine kinase. J Biol Chem (1996) 
271:8809–17. doi:10.1074/jbc.271.15.8809 
6. Matveyenko AV, Liuwantara D, Gurlo T, Kirakossian D, Dalla Man C, 
Cobelli C, et al. Pulsatile portal vein insulin delivery enhances hepatic insulin 
action and signaling. Diabetes (2012) 61:2269–79. doi:10.2337/db11-1462 
7. White MF. The IRS-signalling system: a network of docking proteins that 
mediate insulin action. Mol Cell Biochem (1998) 182:3–11. doi:10.1023/ 
A:1006806722619 
8. Haeusler RA, Accili D. The double life of Irs. Cell Metab (2008) 8:7–9. 
doi:10.1016/j.cmet.2008.06.010 
9. Formisano P, Najjar SM, Gross CN, Philippe N, Oriente F, Kern-Buell CL, et al. 
Receptor-mediated internalization of insulin. Potential role of pp120/HA4, 
a substrate of the insulin receptor kinase. J Biol Chem (1995) 270:24073–7. 
doi:10.1074/jbc.270.41.24073 
10. Choice CV, Howard MJ, Poy MN, Hankin MH, Najjar SM. Insulin stimulates 
pp120 endocytosis in cells co-expressing insulin receptors. J Biol Chem (1998) 
273:22194–200. doi:10.1074/jbc.273.35.22194 
11. Najjar SM, Yang Y, Fernstrom MA, Lee SJ, Deangelis AM, Rjaily GA, et al. 
Insulin acutely decreases hepatic fatty acid synthase activity. Cell Metab (2005) 
2:43–53. doi:10.1016/j.cmet.2005.06.001 
12. Ward GM, Walters JM, Aitken PM, Best JD, Alford FP. Effects of prolonged 
pulsatile hyperinsulinemia in humans. Enhancement of insulin sensitivity. 
Diabetes (1990) 39:501–7. doi:10.2337/diab.39.4.501 
13. Osborne TF. Sterol regulatory element-binding proteins (SREBPs): key 
regulators of nutritional homeostasis and insulin action. J Biol Chem (2000) 
275:32379–82. doi:10.1074/jbc.R000017200 
14. Wong RH, Chang I, Hudak CS, Hyun S, Kwan HY, Sul HS. A role of DNA-PK for 
the metabolic gene regulation in response to insulin. Cell (2009) 136:1056–72. 
doi:10.1016/j.cell.2008.12.040 
15. Brown MS, Goldstein JL. Selective versus total insulin resistance: a 
pathogenic paradox. Cell Metab (2008) 7:95–6. doi:10.1016/j.cmet.2007. 
12.009 
16. Park SY, Cho YR, Kim HJ, Hong EG, Higashimori T, Lee SJ, et al. Mechanism 
of glucose intolerance in mice with dominant negative mutation of 
CEACAM1. Am J Physiol Endocrinol Metab (2006) 291:E517–24. doi:10.1152/
ajpendo.00077.2006 
17. Poy MN, Yang Y, Rezaei K, Fernstrom MA, Lee AD, Kido Y, et al. CEACAM1 
regulates insulin clearance in liver. Nat Genet (2002) 30:270–6. doi:10.1038/
ng840 
5Heinrich et al. CEACAM1 in NAFLD and Obesity
Frontiers in Endocrinology | www.frontiersin.org January 2017 | Volume 8 | Article 8
18. DeAngelis AM, Heinrich G, Dai T, Bowman TA, Patel PR, Lee SJ, et  al. 
Carcinoembryonic antigen-related cell adhesion molecule 1: a link between 
insulin and lipid metabolism. Diabetes (2008) 57:2296–303. doi:10.2337/
db08-0379 
19. Ghosh S, Kaw M, Patel PR, Ledford KJ, Bowman TA, McLnerney MF, et al. 
Mice with null mutation of Ceacam1 develop nonalcoholic steatohepatitis. 
Hepat Med (2010) 2010:69–78. doi:10.2147/HMER.S8902
20. Nagaishi T, Pao L, Lin SH, Iijima H, Kaser A, Qiao SW, et  al. SHP1 
phosphatase-dependent T cell inhibition by CEACAM1 adhesion molecule 
isoforms. Immunity (2006) 25:769–81. doi:10.1016/j.immuni.2006.08.026 
21. Groop LC, Saloranta C, Shank M, Bonadonna RC, Ferrannini E, DeFronzo 
RA. The role of free fatty acid metabolism in the pathogenesis of insulin 
resistance in obesity and noninsulin-dependent diabetes mellitus. J Clin 
Endocrinol Metab (1991) 72:96–107. doi:10.1210/jcem-72-1-96 
22. Scherer T, Lindtner C, Zielinski E, O’Hare J, Filatova N, Buettner C. Short term 
voluntary overfeeding disrupts brain insulin control of adipose tissue lipolysis. 
J Biol Chem (2012) 287:33061–9. doi:10.1074/jbc.M111.307348 
23. Kabir M, Catalano KJ, Ananthnarayan S, Kim SP, Van Citters GW, Dea 
MK, et  al. Molecular evidence supporting the portal theory: a causative 
link between visceral adiposity and hepatic insulin resistance. Am J Physiol 
Endocrinol Metab (2005) 288:E454–61. doi:10.1152/ajpendo.00203.2004 
24. Pereira S, Park E, Mori Y, Haber CA, Han P, Uchida T, et  al. FFA-induced 
hepatic insulin resistance in  vivo is mediated by PKCδ, NADPH oxidase, 
and oxidative stress. Am J Physiol Endocrinol Metab (2014) 307:E34–46. 
doi:10.1152/ajpendo.00436.2013 
25. Najjar SM, Russo L. CEACAM1 loss links inflammation to insulin resistance 
in obesity and non-alcoholic steatohepatitis (NASH). Semin Immunopathol 
(2014) 36:55–71. doi:10.1007/s00281-013-0407-3 
26. Al-Share QY, DeAngelis AM, Lester SG, Bowman TA, Ramakrishnan SK, 
Abdallah SL, et  al. Forced hepatic overexpression of CEACAM1 curtails 
diet-induced insulin resistance. Diabetes (2015) 64:2780–90. doi:10.2337/
db14-1772 
27. Russo L, Ghadieh HE, Ghanem SS, Al-Share QY, Smiley ZN, Gatto-Weis C, 
et al. Role for hepatic CEACAM1 in regulating fatty acid metabolism along the 
adipocyte-hepatocyte axis. J Lipid Res (2016) 57(12):2163–75. doi:10.1194/jlr.
M072066 
28. Bakker LEH, van Schinkel LD, Guigas B, Streefland TCM, Jonker JT, van 
Klinken JB, et al. A 5-day high-fat, high-calorie diet impairs insulin sensitivity 
in healthy, young South Asian men but not in Caucasian men. Diabetes (2014) 
63:248–58. doi:10.2337/db13-0696 
29. Mittelman SD, Van Citters GW, Kim SP, Davis DA, Dea MK, Hamilton-
Wessler M, et al. Longitudinal compensation for fat-induced insulin resistance 
includes reduced insulin clearance and enhanced beta-cell response. Diabetes 
(2000) 49:2116–25. doi:10.2337/diabetes.49.12.2116 
30. Wiesenthal SR, Sandhu H, McCall RH, Tchipashvili V, Yoshii H, Polonsky K, 
et al. Free fatty acids impair hepatic insulin extraction in vivo. Diabetes (1999) 
48:766–74. doi:10.2337/diabetes.48.4.766 
31. Svedberg J, Stromblad G, Wirth A, Smith U, Bjorntorp P. Fatty acids in the 
portal vein of the rat regulate hepatic insulin clearance. J Clin Invest (1991) 
88:2054–8. doi:10.1172/JCI115534 
32. Shanik MH, Xu Y, Skrha J, Dankner R, Zick Y, Roth J. Insulin resistance and 
hyperinsulinemia: is hyperinsulinemia the cart or the horse? Diabetes Care 
(2008) 31(Suppl 2):S262–8. doi:10.2337/dc08-s264 
33. Cook JR, Langlet F, Kido Y, Accili D. Pathogenesis of selective insulin resis-
tance in isolated hepatocytes. J Biol Chem (2015) 290:13972–80. doi:10.1074/
jbc.M115.638197 
34. Wolfrum C, Asilmaz E, Luca E, Friedman JM, Stoffel M. Foxa2 regulates lipid 
metabolism and ketogenesis in the liver during fasting and in diabetes. Nature 
(2004) 432:1027–32. doi:10.1038/nature03047 
35. Weickert MO, Pfeiffer AF. Signalling mechanisms linking hepatic glucose 
and lipid metabolism. Diabetologia (2006) 49:1732–41. doi:10.1007/
s00125-006-0295-3 
36. Perry RJ, Camporez JP, Kursawe R, Titchenell PM, Zhang D, Perry CJ, 
et  al. Hepatic acetyl CoA links adipose tissue inflammation to hepatic 
insulin resistance and type 2 diabetes. Cell (2015) 160:745–58. doi:10.1016/ 
j.cell.2015.01.012 
37. Titchenell PM, Quinn WJ, Lu M, Chu Q, Lu W, Li C, et al. Direct hepato-
cyte insulin signaling is required for lipogenesis but is dispensable for the 
suppression of glucose production. Cell Metab (2016) 23:1154–66. doi:10.1016/ 
j.cmet.2016.04.022 
38. Groop LC, Bonadonna RC, Shank M, Petrides AS, DeFronzo RA. Role of free 
fatty acids and insulin in determining free fatty acid and lipid oxidation in 
man. J Clin Invest (1991) 87:83–9. doi:10.1172/JCI115005 
39. Lester SG, Russo L, Ghanem SS, Khuder SS, DeAngelis AM, Esakov EL, et al. 
Hepatic CEACAM1 over-expression protects against diet-induced fibrosis 
and inflammation in white adipose tissue. Front Endocrinol (2015) 6:116. 
doi:10.3389/fendo.2015.00116 
40. Elam MB, Wilcox HG, Cagen LM, Deng X, Raghow R, Kumar P, et al. Increased 
hepatic VLDL secretion, lipogenesis, and SREBP-1 expression in the corpulent 
JCR:LA-cp rat. J Lipid Res (2001) 42:2039–48. 
41. Horton JD, Goldstein JL, Brown MS. SREBPs: activators of the complete 
program of cholesterol and fatty acid synthesis in the liver. J Clin Invest (2002) 
109:1125–31. doi:10.1172/JCI0215593 
42. Ginsberg HN, Zhang YL, Hernandez-Ono A. Regulation of plasma tri-
glycerides in insulin resistance and diabetes. Arch Med Res (2005) 36:232–40. 
doi:10.1016/j.arcmed.2005.01.005 
43. Matikainen N, Manttari S, Westerbacka J, Vehkavaara S, Lundbom N, Yki-
Jarvinen H, et al. Postprandial lipemia associates with liver fat content. J Clin 
Endocrinol Metab (2007) 92:3052–9. doi:10.1210/jc.2007-0187 
44. Vine DF, Takechi R, Russell JC, Proctor SD. Impaired postprandial apoli-
poprotein-B48 metabolism in the obese, insulin-resistant JCR:LA-cp rat: 
increased atherogenicity for the metabolic syndrome. Atherosclerosis (2007) 
190:282–90. doi:10.1016/j.atherosclerosis.2006.03.013 
45. Biddinger SB, Hernandez-Ono A, Rask-Madsen C, Haas JT, Aleman JO, 
Suzuki R, et al. Hepatic insulin resistance is sufficient to produce dyslipidemia 
and susceptibility to atherosclerosis. Cell Metab (2008) 7:125–34. doi:10.1016/ 
j.cmet.2007.11.013 
46. Gonzalez E, Flier E, Molle D, Accili D, McGraw TE. Hyperinsulinemia leads 
to uncoupled insulin regulation of the GLUT4 glucose transporter and the 
FoxO1 transcription factor. Proc Natl Acad Sci U S A (2011) 108:10162–7. 
doi:10.1073/pnas.1019268108 
47. Xu E, Dubois MJ, Leung N, Charbonneau A, Turbide C, Avramoglu RK, 
et al. Targeted disruption of carcinoembryonic antigen-related cell adhesion 
molecule 1 promotes diet-induced hepatic steatosis and insulin resistance. 
Endocrinology (2009) 150:3503–12. doi:10.1210/en.2008-1439 
48. Emanuelli B, Vienberg SG, Smyth G, Cheng C, Stanford KI, Arumugam 
M, et  al. Interplay between FGF21 and insulin action in the liver regulates 
metabolism. J Clin Invest (2014) 124:515–27. doi:10.1172/JCI67353 
49. Owen BM, Ding X, Morgan DA, Coate KC, Bookout AL, Rahmouni K, 
et  al. FGF21 acts centrally to induce sympathetic nerve activity, energy 
expenditure, and weight loss. Cell Metab (2014) 20(4):670–7. doi:10.1016/ 
j.cmet.2014.07.012 
50. Cornu M, Oppliger W, Albert V, Robitaille AM, Trapani F, Quagliata L, et al. 
Hepatic mTORC1 controls locomotor activity, body temperature, and lipid 
metabolism through FGF21. Proc Natl Acad Sci U S A (2014) 111:11592–9. 
doi:10.1073/pnas.1412047111 
51. Rosenbaum M, Leibel RL. Leptin: a molecule integrating somatic energy 
stores, energy expenditure and fertility. Trends Endocrinol Metab (1998) 
9:117–24. doi:10.1016/S1043-2760(98)00028-9 
52. Choi MS, Kim YJ, Kwon EY, Ryoo JY, Kim SR, Jung UJ. High-fat diet decreases 
energy expenditure and expression of genes controlling lipid metabolism, 
mitochondrial function and skeletal system development in the adipose 
tissue, along with increased expression of extracellular matrix remodelling- 
and inflammation-related genes. Br J Nutr (2015) 113:867–77. doi:10.1017/
S0007114515000100 
53. Heinrich G, Russo L, Castaneda TR, Pfeiffer V, Ghadieh HE, Ghanem SS, 
et al. Leptin resistance contributes to obesity in mice with null mutation of 
carcinoembryonic antigen-related cell adhesion molecule 1. J Biol Chem 
(2016) 291:11124–32. doi:10.1074/jbc.M116.716431 
54. Cha SH, Hu Z, Lane MD. Long-term effects of a fatty acid synthase inhib-
itor on obese mice: food intake, hypothalamic neuropeptides, and UCP3. 
Biochem Biophys Res Commun (2004) 317:301–8. doi:10.1016/j.bbrc.2004. 
03.026 
55. Chakravarthy MV, Zhu Y, Lopez M, Yin L, Wozniak DF, Coleman T, et  al. 
Brain fatty acid synthase activates PPARalpha to maintain energy homeosta-
sis. J Clin Invest (2007) 117:2539–52. doi:10.1172/JCI31183 
6Heinrich et al. CEACAM1 in NAFLD and Obesity
Frontiers in Endocrinology | www.frontiersin.org January 2017 | Volume 8 | Article 8
56. Gao S, Lane MD. Effect of the anorectic fatty acid synthase inhibitor C75 on 
neuronal activity in the hypothalamus and brainstem. Proc Natl Acad Sci U S A 
(2003) 100:5628–33. doi:10.1073/pnas.1031698100 
57. Cohen JC, Horton JD, Hobbs HH. Human fatty liver disease: old questions 
and new insights. Science (2011) 332:1519–23. doi:10.1126/science.1204265 
58. Lau JK, Zhang X, Yu J. Animal models of non-alcoholic fatty liver disease: cur-
rent perspectives and recent advances. J Pathol (2017) 241:36–44. doi:10.1002/
path.4829
59. Anstee QM, Goldin RD. Mouse models in non-alcoholic fatty liver 
disease and steatohepatitis research. Int J Exp Pathol (2006) 87:1–16. 
doi:10.1111/j.0959-9673.2006.00465.x 
60. Heinrich G, Ghosh S, Deangelis AM, Schroeder-Gloeckler JM, Patel PR, 
Castaneda TR, et  al. Carcinoembryonic antigen-related cell adhesion 
molecule 2 controls energy balance and peripheral insulin action in mice. 
Gastroenterology (2010) 139:644–52. doi:10.1053/j.gastro.2010.03.056 
61. Lee SJ, Heinrich G, Fedorova L, Al-Share QY, Ledford KJ, Fernstrom MA, et al. 
Development of nonalcoholic steatohepatitis in insulin-resistant liver-specific 
S503A carcinoembryonic antigen-related cell adhesion molecule 1 mutant 
mice. Gastroenterology (2008) 135:2084–95. doi:10.1053/j.gastro.2008.08.007 
62. Dankner R, Chetrit A, Shanik MH, Raz I, Roth J. Basal-state hyperinsulinemia 
in healthy normoglycemic adults is predictive of type 2 diabetes over a 24-year 
follow-up: a preliminary report. Diabetes Care (2009) 32:1464–6. doi:10.2337/
dc09-0153 
63. Pories WJ, Dohm GL. Diabetes: have we got it all wrong? Hyperinsulinism as 
the culprit: surgery provides the evidence. Diabetes Care (2012) 35:2438–42. 
doi:10.2337/dc12-0684 
64. Corkey BE. Banting lecture 2011: hyperinsulinemia: cause or consequence? 
Diabetes (2012) 61:4–13. doi:10.2337/db11-1483 
65. Marini MA, Frontoni S, Succurro E, Arturi F, Fiorentino TV, Sciacqua A, 
et  al. Differences in insulin clearance between metabolically healthy and 
unhealthy obese subjects. Acta Diabetol (2014) 51:257–61. doi:10.1007/
s00592-013-0511-9 
66. Meistas MT, Margolis S, Kowarski AA. Hyperinsulinemia of obesity is due 
to decreased clearance of insulin. Am J Physiol Endocrinol Metab (1983) 
245:E155–9. 
67. Jones CN, Abbasi F, Carantoni M, Polonsky KS, Reaven GM. Roles of insulin 
resistance and obesity in regulation of plasma insulin concentrations. Am 
J Physiol Endocrinol Metab (2000) 278:E501–8. 
68. Lee CC, Haffner SM, Wagenknecht LE, Lorenzo C, Norris JM, Bergman RN, 
et al. Insulin clearance and the incidence of type 2 diabetes in Hispanics and 
African Americans: the IRAS family study. Diabetes Care (2013) 36:901–7. 
doi:10.2337/dc12-1316 
69. Pivovarova O, Bernigau W, Bobbert T, Isken F, Mohlig M, Spranger J, et al. 
Hepatic insulin clearance is closely related to metabolic syndrome compo-
nents. Diabetes Care (2013) 36:3779–85. doi:10.2337/dc12-1203 
70. Finucane FM, Sharp SJ, Hatunic M, Sleigh A, De Lucia Rolfe E, Aihie Sayer 
A, et  al. Liver fat accumulation is associated with reduced hepatic insulin 
extraction and beta cell dysfunction in healthy older individuals. Diabetol 
Metab Syndr (2014) 6:43. doi:10.1186/1758-5996-6-43 
71. Lee W. The CEACAM1 expression is decreased in the liver of severely 
obese patients with or without diabetes. Diagn Pathol (2011) 6:40. 
doi:10.1186/1746-1596-6-40 
Conflict of Interest Statement: The authors declare that the research was con-
ducted in the absence of any commercial or financial relationships that could be 
construed as a potential conflict of interest.
Copyright © 2017 Heinrich, Ghadieh, Ghanem, Muturi, Rezaei, Al-Share, Bowman, 
Zhang, Garofalo, Yin and Najjar. This is an open-access article distributed under the 
terms of the Creative Commons Attribution License (CC BY). The use, distribution or 
reproduction in other forums is permitted, provided the original author(s) or licensor 
are credited and that the original publication in this journal is cited, in accordance 
with accepted academic practice. No use, distribution or reproduction is permitted 
which does not comply with these terms.
